Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms + [1] |
Target |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), ENPP3 inhibitors(Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 1 | ES | 14 Dec 2023 | |
Solid tumor | Phase 1 | US | 14 Dec 2023 | |
Solid tumor | Phase 1 | FR | 14 Dec 2023 |